According to the current analysis of Reports and Data, the global Extracorporeal Membrane Oxygenation (ECMO) market was valued at USD 290.2 Million in 2020 and is expected to reach USD 385.9 Million by the year 2028, at a CAGR of 3.6%. Extracorporeal membrane oxygenation is a treatment provided for COVID-19, cardiac and respiratory diseases. Increasing the prevalence of target diseases (such as COVID-19, cardiovascular diseases and respiratory diseases), technological advancements, and increasing extracorporeal membrane oxygenation centers across the globe are some of the factors driving the market growth. It is estimated that in the U.S., approximately 1,055,000 individuals will have coronary diseases, including 720,000 new and 335,000 recurrent coronary events. The number of artificial respiration via the help of the device in a developed nation such as the U.S. from the past decade is constantly on rise. With rising technological innovations improved survival rate with extracorporeal membrane oxygenation is another major factor that supports the spread of the adoption of extracorporeal membrane oxygenation in case of medical emergencies such as COVID-19 cases. In South Korea it has been observed that the inpatient with Extracorporeal membrane oxygenation therapy for respiratory failure had improved survival rate from 30.8% to 35.9%.
According to the Extracorporeal Life Support Organization (ELSO), the number of hospitals offering ECMO services reached 264 in 2020, rising from 108 in 2008. Obesity often leads to poor vascular health and an increased risk of cardiovascular disease (CVD). With advent of COVID pandemic the demand for the device is expected to surge further. . However, stringent regulations in developed nations, and high associated cost of the procedure may hinder market growth in developing nations.
The COVID-19 Impact: The sudden outbreak of COVID-19 has reported a significant inclination in the Extracorporeal Membrane Oxygenation worldwide market growth. As COVID-19 can trigger acute respiratory failure and/or acute cardiopulmonary failure, the FDA has stated the new policy for the treatment of COVID-19 patients that allows extracorporeal oxygenation for more than six hours. With the scarcity of ventilators and ascending number of cases, increased need for ECMO is emerging as to be indispensable to ensure the survival of critically ill patients. At HonorHealth (Phoenix) a COVID patient otherwise not responding well over ventilator, got treated through ECMO as a last resort and survived.
As of 15th April 2020, number of COVID-19 cases under extracorporeal membrane oxygenation are 230 in North Americs, 89 in Europe, 14 in Asia-Pacific and 9- in Latin America. On the other hand, with soaring number of COVID cases across the globe it is anticipated that only in U.S. over thirty thousand patients may require extracorporeal machine oxygenation. extracorporeal membrane oxygenation machines have been accepted as an effective treatment of COVID-19 in several countries outside of the U.S., such as China, South Korea, and Japan. Higher raw material pricing, disruption in global supply chain, and restricted transportation with higher excise duties, stringent government regulations and lockdowns in various parts of the world, are among the key factors due to which many economies are facing product shortage. To ensure the spread of awareness about the device’s application in COVID pandemic, the U.S. FDA has included a list of all the devices that are capable of being used for extracorporeal membrane oxygenation therapy to be used for the treatment of COVID-19 patients. Furthermore, technological advancements and financial support from private and public bodies is expected to support the increased production and sale of ECMO devices
In-depth Study of the Competitive Landscape:
The global Extracorporeal Membrane Oxygenation (ECMO) market consists of various market players, which make this business sphere highly competitive. In this section of the report, the authors have provided authentic information on product portfolios, new product innovations, technological capabilities, and product pricing strategies of each of these players. Moreover, it discusses the key strategies implemented by these players, such as mergers acquisitions, joint ventures, collaborations, partnerships, and agreements, to build on their market presence.
Top companies profiled in the report include:
Getinge Group (Sweden), Medtronic plc (Ireland), LivaNova PLC (U.K.), XENIOS AG (Germany), Terumo Corporation (Japan), MicroPort Scientific Corporation (China), NIPRO Corporation (Japan), OriGen Biomedical, Inc. (U.S.), ALung Technologies, Inc. (Germany), and EUROSETS S.r.l. (Italy).
Key Market Regions Covered in the Report:
- North America (U.S., Canada)
- Europe (U.K., Italy, Germany, France, Rest of EU)
- Latin America (Chile, Brazil, Argentina, Rest of Latin America)
- Asia Pacific (India, Japan, China, South Korea, Australia, Rest of APAC)
- The Middle East Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)
Type Outlook (Revenue, USD Million; 2020-2028)
- Venovenous ECMO
- Venoarterial ECMO
- Arteriovenous ECMO
Component Outlook (Revenue, USD Million; 2020-2028)
- Pumps
- Cannula
- Oxygenators
- Gas Blender
- Heat Exchanger
- Pressure Monitor
- Bladder Reservoir
- Controller
- Gas Cylinder
- Others
Application Outlook (Revenue, USD Million; 2020-2028)
- Congenital Diaphragmatic Hernia (CDH)
- Birth Defects of the Heart
- Meconium Aspiration Syndrome (MAS)
- Severe Pneumonia
- Severe Air Leak Problems
- Severe High Blood Pressure in the Arteries of the Lungs (PPHN)
- Others
End Use Outlook (Revenue, USD Million; 2020-2028)
- Pediatric
- Adult
Frequently asked questions addressed in the report:
- What is the revenue growth rate of the global Extracorporeal Membrane Oxygenation (ECMO) market over the forecast period?
- What are the major factors driving the growth of the Global Extracorporeal Membrane Oxygenation (ECMO) Market?
- What are the key challenges impacting the global Extracorporeal Membrane Oxygenation (ECMO) market growth?
- What are the outcomes of the SWOT Analysis and Porter’s Five Forces Analysis conducted in the report?
Request customization of the report @ https://www.reportsanddata.com/request-customization-form/2465
Thank you for reading our report. Do connect with us in case of any more queries about the report and its customization. Our team will ensure the report is well suited to cater to your needs.
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
